We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CureVac’s mRNA-based COVID-19 Vaccine Only 47 Percent Effective
CureVac’s mRNA-based COVID-19 Vaccine Only 47 Percent Effective
CureVac’s much-anticipated messenger RNA-based COVID-19 vaccine, CVnCoV, was only 47 percent effective at preventing symptomatic disease in a sizable trial at its interim analysis, missing success criteria. Meantime, Europe has pre-ordered 225 million doses of the vaccine, which may not achieve regulatory authorization.